Viatris plans for Ozempic, Wegovy generics amid lawsuit from Novo Nordisk over Wegovy

07 Aug 2023

Patent Infringement

Viatris Pharmaceuticals’ applications for generic options for type 2 diabetes drug Ozempic and weight loss drug Wegovy are now under regulatory review, according to the company’s second quarter presentation . If approved, both would be the first generics to market for the blockbuster drugs. But Novo Nordisk has already taken steps to stop Viatris Viatris from bringing a Wegovy generic to market with a lawsuit filed in January in Delaware District Court. In court filings, lawyers for Novo wrote that the lawsuit comes from Viatris’ submission of an abbreviated NDA to the FDA for a Wegovy generic injection prior to the patents’ expiration.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Novo Nordisk A/SViatris Pharmaceuticals Co., Ltd.

Viatris Inc.

[+2]

Indications

Diabetes Mellitus, Type 2

Targets

Drugs

Semaglutide (Novo Nordisk)Trastuzumab-DKST(Biocon Ltd.)

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.